|Title||In the Realm of Psychoneuroimmunology: The Role of Celecoxib as an Add-On Treatment for Bipolar Mania|
|Authors||Al-Alawi, M., Al Sinawi, H. and Rashid, R.|
Bipolar affective disorder (BPAD) is a chronic debilitating psychiatric illness seriously affecting the quality of patients’ life. The available treatment is effective in about half of those suffering from the illness. The neurobiological basis of the disorder is not fully unraveled. With such lacunae, attempts have been made to decipher the underlying neuroimmunological process of the illness as is the case with other mental disorders. As a result, some inflammatory processes have been implicated in the etiology of BPAD, as described in this communication. Subsequently, the role of anti-inflammatory agents such as celecoxib was investigated by treating different phases of BPAD. Given the promising outcomes of several trials and reviews, celecoxib has gained momentum and has been recommended as an adjunctive treatment by some guidelines for treating resistant BPAD cases. This brief communication highlights some of the caveats in the randomized trials using celecoxib as an add-on treatment in bipolar mania specifically, which need to be addressed in future work.
|Journal citation||4, pp. 164-167|
|Digital Object Identifier (DOI)||https://doi.org/10.1159/000494700|
|Web address (URL)||https://doi.org/10.1159/000494700|
|Published||08 Nov 2018|